Biotech Values

[DewDiligence]

AQXP 53% workforce reduction:

https://www.sec.gov/Archives/edgar/data/1404644/000119312518214778/d797814d8k.htm

On July 3, 2018, the Compensation Committee of the Board of Directors of Aquinox Pharmaceuticals…approved a restructuring plan to reduce operating costs and better align the Company’s workforce with the needs of its business following the June 27, 2018 announcement that its Phase 3 LEADERSHIP 301 clinical trial evaluating once-daily, oral rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) failed to meet its primary endpoint. The Company has halted all further development activities with rosiptor.

Under this plan, the Company reduced its workforce by 30 employees (approximately 53%) and closed its office in San Bruno, California.